

1 Laurence M. Rosen (SBN 219683)  
2 **THE ROSEN LAW FIRM, P.A.**  
3 355 South Grand Avenue, Suite 2450  
4 Los Angeles, CA 90071  
5 Telephone: (213) 785-2610  
6 Facsimile: (213) 226-4684  
7 Email: lrosen@rosenlegal.com

8 *Counsel for Plaintiff*

9 UNITED STATES DISTRICT COURT  
10 CENTRAL DISTRICT OF CALIFORNIA

11 CHRIS HASHEM, Individually and on  
12 behalf of all others similarly situated,

13 Plaintiff,

14 v.

15 NMC HEALTH PLC, PRASANTH  
16 MANGHAT, KHALIFA BIN BUTTI,  
17 PRASHANTH SHENOY, H. J. MARK  
18 TOMPKINS, and B. R. SHETTY,

19 Defendants.

No.

**CLASS ACTION COMPLAINT  
FOR VIOLATIONS OF THE  
FEDERAL SECURITIES LAWS**

CLASS ACTION

JURY TRIAL DEMANDED

20  
21  
22  
23  
24  
25  
26  
27  
28

1 Plaintiff Chris Hashem (“Plaintiff”), individually and on behalf of all other  
2 persons similarly situated, by Plaintiff’s undersigned attorneys, for Plaintiff’s  
3 complaint against Defendants (defined below), alleges the following based upon  
4 personal knowledge as to Plaintiff and Plaintiff’s own acts, and information and  
5 belief as to all other matters, based upon, *inter alia*, the investigation conducted  
6 by and through his attorneys, which included, among other things, a review of the  
7 Defendants’ public documents, conference calls and announcements made by  
8 Defendants, public filings, wire and press releases published by and regarding  
9 NMC Health Plc (“NMC” or the “Company”), and information readily obtainable  
10 on the Internet. Plaintiff believes that substantial evidentiary support will exist for  
11 the allegations set forth herein after a reasonable opportunity for discovery.

12 **NATURE OF THE ACTION**

13 1. This is a class action on behalf of persons or entities who purchased  
14 or otherwise acquired publicly traded NMC securities between March 13, 2016  
15 and March 10, 2020, inclusive (the “Class Period”). Plaintiff seeks to recover  
16 compensable damages caused by Defendants’ violations of the federal securities  
17 laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

18 **JURISDICTION AND VENUE**

19 2. The claims asserted herein arise under and pursuant to Sections  
20 10(b) and 20(a) of the Exchange Act (15 U.S.C. §§ 78j(b) and 78t(a)) and Rule  
21 10b-5 promulgated thereunder by the SEC (17 C.F.R. § 240.10b-5).

22 3. This Court has jurisdiction over the subject matter of this action  
23 pursuant to 28 U.S.C. § 1331, and Section 27 of the Exchange Act (15 U.S.C.  
24 §78aa).

25 4. This Court has jurisdiction over each defendant named herein  
26 because each defendant has sufficient minimum contacts with this District so as  
27

28

1 to render the exercise of jurisdiction by this Court permissible under traditional  
2 notions of fair play and substantial justice.

3 5. Venue is proper in this judicial district pursuant to 28 U.S.C. §  
4 1391(b) and Section 27 of the Exchange Act (15 U.S.C. § 78aa(c)) as the alleged  
5 misstatements entered and the subsequent damages took place in this judicial  
6 district.

7 6. In connection with the acts, conduct and other wrongs alleged in this  
8 complaint, Defendants, directly or indirectly, used the means and  
9 instrumentalities of interstate commerce, including but not limited to, the United  
10 States mails, interstate telephone communications and the facilities of the  
11 national securities exchange.

12 **PARTIES**

13 7. Plaintiff, as set forth in the accompanying certification, incorporated  
14 by reference herein, purchased NMC securities during the Class Period and was  
15 economically damaged thereby.

16 8. Defendant NMC, together with its subsidiaries, purports to provide  
17 healthcare services in the United Arab Emirates, the United Kingdom, Spain, and  
18 internationally. The Company purports to own and manage approximately 200  
19 healthcare facilities, including hospitals, medical centers, long term care facilities,  
20 day surgery centers, fertility clinics, and home health services providers. The  
21 Company purports to offer medical services as well as research and medical  
22 services in the field of gynecology, obstetrics, and human reproduction; and  
23 management services to hospitals, as well as retail pharmaceutical goods.

24 9. NMC is incorporated in England and Wales with its head office is  
25 located at Devonshire House, Level 1 One Mayfair Place, London W1J 8AJ,  
26 United Kingdom. NMC's American Depositary Shares ("ADSs") trade on the  
27 OTC Pink under the ticker symbol "NMHLY."  
28

1           10. Defendant Prasanth Manghat (“Manghat”) served as the Company’s  
2 Chief Executive Officer (“CEO”) and Executive Director from March 2017 until  
3 February 2020. Previously, Manghat had served as the Company’s Deputy CEO  
4 and Chief Financial Officer (“CFO”).

5           11. Defendant Khalifa Bin Butti, also known as Khalifa Butti Omeir Bin  
6 Yousef and Khalifa Butti al-Muhairi, (“K. Bin Butti”) served as the Company’s  
7 Executive Vice Chairman from July 2017 until February 2020 and as a Director  
8 from June 2017 until February 2020. K. Bin Butti purportedly owned 14.7% of  
9 NMC as of March 6, 2019. Together with Defendant Shetty (defined below) and  
10 H.E. Saeed Bin Butti (“H.E. Bin Butti”), K. Bin Butti was noted as one of “the  
11 Company’s immediate and ultimate controlling part[ies]” in the Annual Reports  
12 2015, 2016, 2017, and 2018.

13           12. Defendant Prashanth Shenoy (“Shenoy”) has served as the  
14 Company’s Chief Financial Officer (“CFO”) since August 2017. Previously,  
15 Shenoy had served as the Company’s Deputy CFO.

16           13. Defendant H. J. Mark Tompkins (“Tompkins”) has served as the  
17 Company’s Non-Executive (Joint) Chairman of the Board during the Class  
18 Period.

19           14. Defendant B. R. Shetty (“Shetty”) founded the Company and served  
20 as the Company’s CEO and Executive Vice Chairman until March 2017 and  
21 served as the Company’s Non-Executive Joint Chairman of the Board from  
22 March 2017 until February 2020. Shetty purportedly owned 19.2% of NMC as of  
23 March 6, 2019. Along with Defendant K. Bin Butti and H.E. Bin Butti, Shetty  
24 was noted as one of the “the Company’s immediate and ultimate controlling  
25 part[ies]” in the Annual Reports 2015, 2016, 2017, and 2018.

26           15. Defendants Manghat, K. Bin Butti, Shenoy, Tompkins, and Shetty  
27 are collectively referred to herein as the “Individual Defendants.”  
28



**Materially False and Misleading**  
**Statements Issued During the Class Period**

1  
2  
3 20. On or around March 13, 2016, NMC released its Annual Report &  
4 Accounts 2015 (“Annual Report 2015”).

5 21. In the Annual Report 2015, Defendant Tompkins included his  
6 Chairman’s 2015 report to shareholders (“Chairman’s Report 2015”). In his  
7 Chairman’s Report 2015, Defendant Tompkins stressed the Company’s strong  
8 financial base, strong risk management, organic expansion and acquisitions.

9 22. In particular, Defendant Tompkins wrote the following in his  
10 Chairman’s Report 2015 about the Company’s strong financial base:

11 Any period of substantial growth and capital development needs to  
12 be progressed against a background of a strong financial base.

13 \* \* \*

14  
15 This strong financial base enabled the Company to restructure  
16 existing loans, reduce its cost of funds and create additional  
17 headroom *to ensure that the Group is conservatively financed*.

18 (Emphasis added.)

19 23. Regarding the Company’s risk management, Tompkins wrote the  
20 following in his Chairman’s Report 2015, in pertinent part:

21 In Q4, 2014 the management team, supported by  
22 [PricewaterhouseCoopers], implemented a full risk identification  
23 process with the risks facing the business developed through a  
24 bottom-up/top-down review process which has been, and will be,  
25 reviewed during each financial year. There have been a few changes  
26 to the Group’s risk profile in the last 12 months including specific  
27 focus on those risks which are inherent as part of an acquisitive  
28 strategy for growth. A list of the risks facing the Group, how these  
are mitigated and what effect the principal risks could have on the  
Group are set out on pages 37 to 39. *The Board has taken a*

1 *proactive stance in considering risk, and the board sees this as an*  
2 *essential element in the successful development of the Group and in*  
3 *creating long term value for our shareholders.*

4 (Emphasis added.)

5 24. The Annual Report 2015 expanded on Tompkins' statements  
6 regarding risk management, stating in pertinent part:

7 *NMC follows a conservative approach in risk taking and has*  
8 *implemented controls and mitigation strategies in order to reduce*  
9 *those risks.*

10 \* \* \*

11 There have been no material changes made to the Group's strategic  
12 risk register in 2015 or changes to the relative importance or  
13 materiality of any particular risk.

14 (Emphasis added.)

15 25. The Annual Report 2015, regarding potential conflicts of interest,  
16 stated the following:

17 The Board are aware of the interest that some Directors have in other  
18 businesses in which they have invested. Any conflicts of interest and  
19 related party transactions that may arise are monitored by:

- 20 • A list of other relevant interests of each Director being circulated to  
21 the Board at each of its Board Meetings;  
22 • Each of the Directors are asked to confirm that they have no other  
23 interests which would conflict them for the purposes of any item to  
24 be discussed at the meeting; where such conflict is reported, the  
25 respective Director is not permitted to take part in the consideration  
26 of that matter by the Board;  
27 • Each Director discloses to the Board any related party transactions  
28 in which they are connected, and such transactions are reported in the  
Group's financial statements.

1 Whilst Directors on the Board have other business interests, the  
2 Board do not consider that these, nor the time commitment that they  
3 require, affect the ability of such Directors to undertake their role or  
4 comply with their statutory obligations.

5 26. The Annual Report 2015 touted the Company's "strengthening of  
6 internal controls," stating in pertinent part:

7 In recent years, as the Group has progressed an organic and inorganic  
8 growth strategy, in order to strengthen the governance and control  
9 structure further across the Group, management have progressively  
10 been:

- 11 • incorporating additional key internal controls into its financial and  
12 operational processes;
- 13 • implementing new policies and procedures covering all aspects of  
14 the Group's accounting policies and controls;
- 15 • extending its Quality Team and the Group's Quality and Clinical  
16 Governance processes;
- 17 • enhancing the Group's Internal Audit function which  
18 independently reviews and monitors key business processes[.]

19 27. The Annual Report 2015 also listed several "key elements" of its  
20 controls and risk mitigation. These key elements included the following:

- 21 • A defined process for controlling capital expenditure, including  
22 appropriate authorization levels, which is monitored and approved by  
23 the Board as appropriate.

24 \* \* \*

- 25 • A formal process through which approval for organic and inorganic  
26 expansion projects is given. A formal transaction request paper is  
27 produced including details of the proposed transaction, how the  
28 transaction will be financed, market studies, strategic benefits and  
longer term effects on the Group, due diligence and key transaction  
risks are considered.

\* \* \*

- A delegation of authority which provides that very few individuals within the organisation have payment approval authority. Access to cash is also restricted to very few individuals. All material payments, including within the acquired businesses, are restricted to the senior management team.

28. The Annual Report 2015 was attested to by the Board of Directors in full, and in particular with the Board “confirming to the best of [their] knowledge:”

- The financial statements, prepared in accordance with the International Financial Reporting Standards as adopted by the EU, ***give a true and fair view of the assets, liabilities, financial position*** and profit or loss of the Company and the undertakings included in the consolidation taken as a whole; and
- The Strategic Report includes a fair review of the development and performance of the business and the position of the Company and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties they face.

(Emphasis added.)

29. The Annual Report 2015 stated the following regarding related party transactions:

#### RELATED PARTY TRANSACTIONS

These represent transactions with related parties, including major shareholders and senior management of the Group, and entities controlled, jointly controlled or significantly influenced by such parties, or where such parties are members of the key management personnel of the entities. Pricing policies and terms of all transactions are approved by the management of the Group.

The Company’s immediate and ultimate controlling party is a group of three individuals (H.E. Saeed Bin Butti, Dr B.R. Shetty and Mr Khalifa Bin Butti) who are all shareholders and of whom one is a director of the Company and who together have the ability to control the company. As the immediate and ultimate controlling party is a

1 group of individuals, it does not produce consolidated financial  
2 statements.

3 RELATIONSHIP AGREEMENT

4 The Controlling Shareholders and the Company have entered into a  
5 relationship agreement, the *principal purpose of which is to ensure*  
6 *that the Company is capable of carrying out its business*  
7 *independently of the Controlling Shareholders and that*  
8 *transactions and relationships with the Controlling Shareholders*  
9 *are at arm's length and on a normal commercial basis.*

10 *In accordance with the terms of the relationship agreement, the*  
11 *Controlling Shareholders have a collective right to appoint a*  
12 *number of Directors to the Board depending upon the level of their*  
13 *respective shareholdings. This entitlement reduces or is removed as*  
14 *the collective shareholdings reduce.* The relationship agreement  
15 includes provisions to ensure that the Board remains independent.

16 \* \* \*

17 RELATED PARTY TRANSACTIONS

18 These represent transactions with related parties, i.e. major  
19 shareholders and senior management of the Company, and entities  
20 controlled, jointly controlled or significantly influenced by such  
21 parties. Pricing policies and terms of all transactions are approved by  
22 the management of the Company.

23 The Company's immediate and ultimate controlling party is a group  
24 of three individuals (H.E. Saeed Bin Butti, Dr B.R. Shetty and Mr  
25 Khalifa Bin Butti) who are all shareholders and of whom one is a  
26 director of the Company and who together have the ability to control  
27 the Company.

28 (Emphasis added.)

30. The Annual Report 2015 stated that the Company's "CASH AND  
CASH EQUIVALENTS AT 31 DECEMBER [2015]" was \$84,024,000.

31. On or around March 7, 2017, NMC released its Annual Report &

1 Accounts 2016 (“Annual Report 2016”).

2 32. In the Annual Report 2016, the Non-Executive Chairman, Tompkins,  
3 included his Chairman’s 2016 report to shareholders (“Chairman’s Report 2016”).  
4 In his Chairman’s Report 2016, Tompkins stressed the Company’s acquisitions,  
5 organic expansion, and financial stability.

6 33. In particular, Tompkins wrote the following, in pertinent part, about  
7 the Company’s financial stability in his Chairman’s Report 2016 report to  
8 shareholders:

9 In 2016, the Board have been keen to retain flexibility with regards to  
10 financing, as well as ensuring that the Group is well funded for both  
11 general working capital purposes and to facilitate strategic  
12 acquisitions.

13 34. The Annual Report 2016 stated the following regarding risk  
14 management, in pertinent part:

15 *NMC follows a conservative approach in risk taking and has*  
16 *implemented controls and mitigation strategies in order to reduce*  
17 *those risks.*

18 \* \* \*

19 There have been no material changes made to the Group’s strategic  
20 risk register in 2016.

21 (Emphasis added.)

22 35. The Annual Report 2016 reiterated the Annual Report 2015 regarding  
23 the Board and potential conflicts of interest, stated in pertinent part:

24 The Board are aware of the interest that some Directors have in other  
25 businesses in which they have invested. Any conflicts of interest and  
26 related party transactions that may arise are monitored by:

- 27 • A list of other relevant interests of each Director being circulated to  
28 the Board at each of its Board Meetings;

- 1 • Each of the Directors are asked to confirm that they have no other  
2 interests which would conflict them for the purposes  
3 of any item to be discussed at the meeting; where such conflict is  
4 reported, the respective Director is not permitted to take part in the  
5 consideration of that matter by the Board;
- 6 • Each Director discloses to the Board any related party transactions  
7 in which they are connected, and such transactions are reported in the  
8 Group’s financial statements.

9 Whilst Directors on the Board have other business interests, the  
10 Board do not consider that these, nor the time commitment that they  
11 require, affect the ability of such Directors to undertake their role or  
12 comply with their statutory obligations.

13 36. The Annual Report 2016, in a section approved by the Board and  
14 signed on its behalf by Tompkins, also listed and reiterated several “key elements”  
15 of its controls and risk mitigation from the Annual Report 2015. These key  
16 elements included the following:

- 17 • A defined process for controlling capital expenditure, including  
18 appropriate authorisation levels, which is monitored and approved by  
19 the Board as appropriate.

20 \* \* \*

- 21 • A formal process through which approval for organic and inorganic  
22 expansion projects is given. A formal transaction request paper is  
23 produced including details of the proposed transaction, how the  
24 transaction will be financed, market studies, strategic benefits and  
25 longer term effects on the Group, due diligence and key transaction  
26 risks are considered.

27 \* \* \*

- 28 • A delegation of authority which provides that very few individuals  
within the organisation have significant payment approval authority.  
Access to cash is also restricted to very few individuals. All material  
payments, including within the acquired businesses, are restricted to  
the senior management team.



1 RELATED PARTY TRANSACTIONS

2 These represent transactions with related parties, i.e. major  
3 shareholders and senior management of the Company, and entities  
4 controlled, jointly controlled or significantly influenced by such  
5 parties. Pricing policies and terms of all transactions are approved by  
6 the management of the Company.

7 The Company's immediate and ultimate controlling party is a group  
8 of three individuals (H.E. Saeed Bin Butti, Dr BR Shetty and Mr  
9 Khalifa Bin Butti) who are all shareholders and of whom one is a  
10 director of the Company and who together have the ability to control  
11 the Company. As the immediate and ultimate controlling party is a  
12 group of individuals, it does not produce consolidated financial  
13 statements.

14 (Emphasis added.)

15 39. The Annual Report 2016 stated that the Company's "CASH AND  
16 CASH EQUIVALENTS AT 31 DECEMBER [2016]" as \$433,403,000.

17 40. On or around March 6, 2018, NMC released its Annual Report &  
18 Accounts 2017 ("Annual Report 2017").

19 41. In the Annual Report 2017, the then-new CEO, Defendant Manghat,  
20 included his Chief Executive Officer's Review to shareholders. Therein, Manghat  
21 stressed the Company's growth. In particular, he stated the following:

22 VIEWING THE FUTURE WITH OPTIMISM, DESPITE ALL  
23 CHALLENGES

24 NMC has moved from success to success over the past many years  
25 and I see no reason why this should change in the foreseeable future,  
26 despite an otherwise challenging environment.

27 \* \* \*

28 The Company continues to benefit from ready access to debt  
financing and a supportive shareholder base that we will not take for  
granted. While *we continue to apply strict criteria to our expansion  
opportunities, this backdrop gives us confidence in addressing any*

1 *future funding requirements to support our ambitious growth*  
2 *plans.*

3 (Emphasis added.)

4 42. The Annual Report 2017 stated the following, in pertinent part,  
5 regarding risk management: NMC follows a conservative approach in risk taking  
6 and has implemented controls and mitigation strategies in order to reduce those  
7 risks.

8 43. The Annual Report 2017 stated the following, in pertinent part,  
9 regarding internal controls:

10 The Board and management team have strengthened internal controls  
11 and kept approach to risk under review during the period of sustained  
12 growth and integration.

13 \* \* \*

14  
15 The Board has overall responsibility for the Group's systems of  
16 internal control and on behalf of the Board, the Audit Committee has  
17 been engaged in the process of ensuring that management have  
18 established continuous processes for identifying, evaluating and  
19 managing the risks the Group faces. These processes include the  
20 reporting from the finance department on Group performance, the  
21 work of the internal auditors and issues identified by the external  
22 auditors to the extent covered by their audit work. The Board is  
23 responsible for monitoring the ongoing effectiveness of these systems  
24 and for conducting a formal annual review of the effectiveness of the  
25 Group's internal controls.

26 \* \* \*

27 In reviewing the effectiveness of the internal controls in place during  
28 the year, the Audit Committee considered, amongst other matters,  
manual controls in place, the independence of the separate operating  
units, the delegation of authority, the balance of centralised and  
decentralised systems and the reporting process in relation to  
exceptional items.



1 (Emphasis added.)

2 46. The Annual Report 2017 reiterated the Annual Reports 2015 and  
3 2016 regarding related party transactions, stated the following:

4 RELATED PARTY TRANSACTIONS

5 These represent transactions with related parties, including major  
6 shareholders and senior management of the Group, and entities  
7 controlled, jointly controlled or significantly influenced by such  
8 parties, or where such parties are members of the key management  
9 personnel of the entities. Pricing policies and terms of all transactions  
10 are approved by the management of the Group.

11 The Company's immediate and ultimate controlling party is a group  
12 of three individuals (H.E. Saeed Bin Butti, Dr BR Shetty and Mr  
13 Khalifa Bin Butti) who are all shareholders and of whom two are  
14 directors of the Company and who together have the ability to control  
15 the company. As the immediate and ultimate controlling party is a  
16 group of individuals, it does not produce consolidated financial  
17 statements.

18 RELATIONSHIP AGREEMENT

19 The Controlling Shareholders and the Company have entered into a  
20 relationship agreement, *the principal purpose of which is to ensure  
21 that the Company is capable of carrying out its business  
22 independently of the Controlling Shareholders and that  
23 transactions and relationships with the Controlling Shareholders  
24 are at arm's length and on a normal commercial basis.*

25 *In accordance with the terms of the relationship agreement, the  
26 Controlling Shareholders have a collective right to appoint a  
27 number of Directors to the Board depending upon the level of their  
28 respective shareholdings. This entitlement reduces or is removed as  
the collective shareholdings reduce.* The relationship agreement  
includes provisions to ensure that the Board remains independent.

\* \* \*

RELATED PARTY TRANSACTIONS

1 These represent transactions with related parties, i.e. major  
2 shareholders and senior management of the Company, and entities  
3 controlled, jointly controlled or significantly influenced by such  
4 parties. Pricing policies and terms of all transactions are approved by  
5 the management of the Company.

6 The Company's immediate and ultimate controlling party is a group  
7 of three individuals (H.E. Saeed Bin Butti, Dr BR Shetty and Mr  
8 Khalifa Bin Butti) who are all shareholders and of whom two are  
9 directors of the Company and who together have the ability to control  
10 the Company.

11 (Emphasis added.)

12 47. The Annual Report 2017 also added the following regarding related  
13 party transactions, in pertinent part:

14 TERMS AND CONDITIONS OF TRANSACTIONS WITH  
15 RELATED PARTIES

16 *The sales to and purchases from related parties are made on terms  
17 equivalent to those that prevail in arm's length transactions.*

18 (Emphasis added.)

19 48. The Annual Report 2017 stated that the Company's "CASH AND  
20 CASH EQUIVALENTS AT 31 DECEMBER [2017]" as \$206,462,000.

21 49. On or around March 6, 2019, NMC released its Annual Report &  
22 Accounts 2018 ("Annual Report 2018").

23 50. The Annual Report 2018 stated the following, in pertinent part,  
24 regarding risk management:

25 Risk management is an integral part of the success of our strategic  
26 journey

27 The Board consider the identification and mitigation of material risks  
28 and uncertainties faced by the Group as a key issue to be monitored  
at all levels of the organization.

51. The Annual Report 2018, reiterated the Annual Reports of 2015,

1 2016, and 2017 and listed many principal risks and their mitigations. These  
2 controls and mitigations included, in pertinent part:

- 3 • Board oversight in approving and monitoring strategic projects  
4 • Project management controls  
5 • Detailed market and business appraisal and comprehensive due  
6 diligence processes

7 \* \* \*

- 8 • Full due diligence

9 \* \* \*

- 10 • Rigorous analysis of value of the acquisition  
11 • Focus on the corporate cultures involved

12 52. The Annual Report 2018 touted the internal controls of the Company,  
13 stating in pertinent part:

14 The Board and management team have strengthened internal controls  
15 and kept approach to risk under review during the period of sustained  
16 growth and integration.

17 53. The Annual Report 2018, reiterated the Annual Reports 2015, 2016,  
18 and 2017 regarding the Board and potential conflicts of interest, stated in pertinent  
19 part:

20 The Board are aware that some Directors have interests in other  
21 businesses in which they have invested. Any conflicts of interest and  
22 related party transactions that may arise are monitored with:

- 23 • Each of the Directors are asked to confirm that they have no other  
24 interests which would conflict them for the purposes of any item to  
25 be discussed at the meeting; where such conflict is reported, the  
26 respective Director is not permitted to take part in the consideration  
27 of that matter by the Board;

1 • Each Director discloses to the Board any related party transactions  
2 in which they are connected, and such transactions are reported in the  
3 Group’s financial statements.

4 Whilst Directors on the Board have other business interests, the  
5 Board do not consider that these, nor the time commitment that they  
6 require, affect the ability of such Directors to undertake their role or  
7 comply with their statutory obligations.

8 54. The Annual Report 2018 stated the following regarding the Board  
9 and potential conflicts of interest, in pertinent part:

10 Alignment of risk assurance with business growth

11 While progressing its organic and inorganic growth strategy, over the  
12 last two years the Group has dedicated significant resources to  
13 integrating its recently acquired facilities while consolidating the  
14 market position of its legacy facilities, mainly in the UAE. Further, as  
15 the risks that the Group is exposed to continue to evolve (mainly due  
16 to macro-economic uncertainty and the uncertainty resulting from  
17 regulatory and technological disruption in the healthcare sector) the  
18 Group is constantly re-evaluating the design effectiveness of key  
19 controls.

20 55. The Annual Report 2018 reiterated the Annual Reports 2015, 2016,  
21 and 2017 and listed several “key elements” of its controls and risk mitigation.

22 These key elements included the following:

- 23 • Approval and review of the annual budget and long-term forecasts;
- 24 • Group Strategy including the risks and risk mitigation in relation to  
25 the same; and
- 26 • Capital expenditure, financial structuring and acquisition and  
27 investment decisions.
- 28 • Formalised delegations of authority and lines of accountability as  
part of the Group’s “cluster management structure” provides a  
mechanism to monitor performance and operations of a manageable  
number of facilities in sufficient detail covering monthly operational  
and financial reporting including monthly comparison of results and  
against budget and forecast, and a review of key KPIs.

\* \* \*

- Policies, procedures and controls covering:
- The preparation of financial statements of each subsidiary in accordance with IFRS, local tax and regulatory requirements (a complete audit is carried out by the auditors of significant subsidiaries for the purposes of the Group's year-end financial statement);
- The preparation of 20 standardized monthly/daily reports in accordance with accounting policies of the Group, which are formalized in a Group accounting manual given to all the subsidiaries. This accounting manual is regularly updated to incorporate any changes to IFRS and regulation;
- The formal process for organic and inorganic expansion projects with full assessments of potential acquisitions or other material investments including due diligence, financing, market studies, risk analysis, strategic benefits to the Group;
- The Group's mitigation plans with respect to its strategic risks, including cyber risks and protection of personal data; and
- The Group's long term viability and going concern basis of accounting. These are conducted using both internal resources and external consultants.

\* \* \*

Therefore, all of our facilities and businesses we have an appropriate and relevant structure to provide effective and efficient management and clear lines of accountability of both clinical and non-clinical areas. The Senior Management Team believes that these divisions of responsibility at both facility and corporate levels provide a natural check and balance across all internal control areas.

56. The Annual Report 2018 stated the following regarding the Company's internal controls, in pertinent part:

In reviewing the effectiveness of the internal controls in place during the year, the Audit Committee considered, amongst other matters, the enhancements to the control framework, manual controls in place, the independence of the separate operating units, the delegated

1 authorities, the balance of centralised and decentralised systems and  
2 the reporting process in relation to exceptional items.

3 \* \* \*

4 The Board has reviewed the effectiveness of the Group's systems of  
5 internal controls for the 2018 financial year, in light of the key  
6 elements of the Group's internal controls outlined above. Given the  
7 additional internal controls that have been incorporated into the  
8 Group's financial and operational reporting process, such that  
9 sufficient internal controls were in place to monitor the Group's key  
10 risks, the Board believes, having evaluated the both the design and  
11 operating effectiveness of the internal controls and procedures, that  
12 these were effective during the period covered by this report. The  
13 Board also believes that the process undertaken by the Board and its  
14 Committees to monitor the internal control environment, accords  
15 with the guidance provided in the FRC's Guidance on Risk  
16 Management, Internal Control and Related Financial and Business  
17 Reporting.

18 57. The Annual Report 2018 stated that the Company's "CASH AND  
19 CASH EQUIVALENTS AT 31 DECEMBER [2018]" as \$308,076,000.

20 58. The Annual Report 2018 listed \$4,679,000 under "Finance lease  
21 liability" on 31 December 2018.

22 59. On or around August 22, 2019, NMC released its Financial Report  
23 for the Six Months Ended 30 June 2019 ("H1 2019").

24 60. The H1 2019, updated its lease liabilities by adding \$352,203,000.  
25 This was noted as "[f]ollowing a review of lease data validation during the IFRS  
26 16 transition process, additional lease payments were identified which were  
27 previously not part of operating lease commitments."

28 61. On November 11, 2019, NMC issued a press release entitled  
"Progress on key governance initiatives; Enhanced disclosure on Supply Chain  
Financing being utilized by NMC's Distribution suppliers[.]" (the "November

1 2019 Press Release”). The November 2019 Press Release was meant, in part, to  
2 “provide[] greater clarity on Supply Chain Financing utilized by the company’s  
3 non-healthcare, Distribution suppliers.”

4 62. The November 2019 Press Release explained its suppliers use of  
5 supply chain financing, stating in pertinent part:

6 [I]n order to support its vendors and facilitate the stringent demands  
7 of such contracts, NMC permits receivable financing for its suppliers  
8 through supply chain programs. Key features of all such programs  
include:

- 9
- 10 - Financing is arranged after NMC guarantees payment to the  
supplier for the full provision of contracted goods/services
  - 11 - All supply chain financing arrangements are initiated by suppliers -  
All costs of supply chain financing are always borne by the suppliers
  - 12 - The financing is non-recourse to NMC
  - 13 - NMC supports suppliers’ initiatives for supply chain financing  
14 through reputed platforms

15 63. The statements contained in ¶¶21-62 were materially false and/or  
16 misleading because they misrepresented and failed to disclose the following  
17 adverse facts pertaining to the Company’s business, operations and prospects,  
18 which were known to Defendants or recklessly disregarded by them. Specifically,  
19 Defendants made false and/or misleading statements and/or failed to disclose  
20 that: (1) the Company lacked effective internal controls and risk management; (2)  
21 the Company engaged in undisclosed and extensive related party and de facto  
22 related party transactions; (3) NMC’s debts were significantly understated and  
23 obfuscated; (4) NMC’s cash-on-hand figures were overstated; (5) NMC’s  
24 principal shareholders were not accurately reporting or accounting their interests  
25 or stakes in the Company; (6) NMC did not review or know their principal  
26 shareholders interests or stakes in the Company; (7) consequently, the Company  
27 was not enforcing its Relationship Agreement with the principal shareholders;  
28

1 and (8) as a result, Defendants' statements about its business, operations, and  
2 prospects, were materially false and misleading and/or lacked a reasonable basis  
3 at all relevant times.

#### 4 **THE TRUTH EMERGES**

5 64. On December 17, 2019, Muddy Waters Capital LLC ("Muddy  
6 Waters") published a report (the "Report") explaining that NMC had misled  
7 investors and failed to disclose: (i) its lack of internal controls; (ii) (de facto)  
8 related party transactions; (iii) its true debt burden; (iv) its true cash-on-hand and  
9 asset values; and (v) its use of reverse factoring.

10 65. The Report noted that NMC's build-out costs of NMC Royal  
11 Women's Hospital (then-named Brightpoint Hospital) were double the market  
12 price – as opposed to NMC's continued statements regarding its internal controls  
13 and lack of improper related party transactions. Muddy Waters stated the  
14 following regarding this transaction's costs, in pertinent part:

15 Reasonably sophisticated hospitals in the UAE seem to cost \$3,000  
16 to \$4,000 per square meter to build on an all-in cost basis, and the  
17 trend is broadly consistent across metropolitan areas in the Gulf  
18 states. We calculate that NMC Royal Women's, on the other hand,  
19 cost \$7,700 per square meter. This is more than double the average  
20 cost of the group of hospitals we examined.

21 66. The primary contractor for that project was Modular Concepts, LLC  
22 ("Modular Concepts"), a Defendant Shetty controlled company. The Report noted  
23 that Modular Concepts has built many hospitals for NMC and its management. In  
24 fact, according to the Report, relying on the Indian credit rating agency ICRA,  
25 NMC provides 80% of Modular Concepts revenues. Modular Concepts is also  
26 30% owned by Pradeep Rai ("Rai"), NMC's Head of Procurement. Rai is also  
27 Defendant Shetty's long-time confidant and a non-blood relative.

28 67. The Report noted that the Royal Women's Hospital project also

1 included the KBBO Group, a Defendant K. Bin Butti controlled company.

2 68. The Report noted that in March 2018, NMC acquired 70% of Premier  
3 Care Home Medical and Health Care LLC (“Premier”) for \$36.4 million cash. The  
4 sole advisor to the transaction was Guggenheim KBBO Partners Investment  
5 Banking – a joint venture of KBBO Group. Premier was founded in 2014 and  
6 91% of the sale was for intangibles. The Report found that Premier’s facility was  
7 only 280 square meters and employed only nine people – and the facility did not  
8 have authorization to conduct medical procedures. In November 2018, NMC  
9 ceded a 1% share of Premier to H.E. Bin Butti. In November 2019, NMC  
10 purchased another 30% stake in Premier.

11 69. The Report noted that in 2018, NMC acquired 70% of CosmeSurge  
12 from KBBO Group for \$170 million (12x EBIDA) without any third-party  
13 valuation.

14 70. The Report noted that Muddy Waters added up NMC’s financial  
15 statements and determined NMC to have \$491 million cash-on-hand at year-end  
16 2018. However, NMC’s interest expense of its debt is 5.7% and the Company’s  
17 annual interest income average was 0.77%. The Report noted that NMC’s interest  
18 income is too low for its reported cash balances.

19 71. According to the Report, following the Aspen acquisition, NMC has  
20 not included the approximately \$320 million finance leases the Company  
21 inherited. The Report claims that this is in addition to the \$352.2 million of  
22 operating leases which NMC failed to include in its Annual Report 2018 but then  
23 disclosed in its H1 2019. Moreover, the Report claims that the undiscounted  
24 liability NMC holds from the Aspen acquisition is approximately \$450 million,  
25 not \$350 million (as of Fiscal Year 2018, Aspen’s filings included minimum non-  
26 cancellable undiscounted lease payments of £353 million).

27 72. The Report noted that, as opposed to long-standing impressions,  
28

1 NMC has been utilizing supply chain financing facilities, i.e. “reverse factoring.”

2 The Report stated in pertinent part:

3 We found reverse factoring facilities for NMC arranged by Credit  
4 Suisse and Channel Finance S.A. Both are recourse to NMC.

5 \* \* \*

6 The Moody’s analyst recently confirmed his understanding that NMC  
7 does not engage in reverse factoring. However, a July 2019 sell-side  
8 report on NMC mentioned two Credit Suisse supply chain finance  
9 funds that own payables of NMC; NMC then apparently denied this  
10 was reverse factoring because the payables were not tied to a single  
11 supplier, which the sell-side analyst dismissed as a “borderline  
12 technicality”.

13 The reality is that NMC does engage in reverse factoring, and it goes  
14 beyond the Credit Suisse amounts. In addition to the Credit Suisse  
15 funds, we found a facility issued by an entity called Channel Finance.  
16 Just as importantly, we suspect that NMC’s reported debt does not  
17 include these reverse factoring facilities. Interestingly, in November  
18 2019, the notes financing the facility were de-listed, which could be  
19 an attempt to conceal this facility.

20 73. Reverse factoring, as summarized by a *Barron’s* article covering the  
21 Report, is described as:

22 [A] third party pays off the company’s suppliers early, and the  
23 company pays the financier back at a later date. . . In short, reverse  
24 factoring transactions allow companies to put off paying suppliers for  
25 longer, while suppliers get paid on time.

26 Meanwhile, accounting and credit-rating firms are starting to express  
27 some significant concerns about supply-chain finance and reverse  
28 factoring. In particular, they are worried that companies that use this  
technique are not disclosing an accurate picture of their total debt  
loads. There are also worries because of the role reverse factoring  
played in the high-profile collapses of the U.K.’s Carillion and  
Spain’s Abengoa.

\* \* \*

1  
2 And *while reverse factoring can boost company cash in the short*  
3 *term, it comes with risks if a company falls into distress*, the  
4 Moody’s analysts wrote.

5 “Many non-financial corporates have created a ‘tiger trap’ financing  
6 arrangement,” they said. “With inadequate disclosure, the [reverse  
7 factoring] facility can lie hidden in the capital structure until...[it  
8 leaves] a big liquidity hole which magnifies and intensifies the  
underlying problem.”

9 (Emphasis added.)

10 74. On this news, NMC ADSs fell \$11.68, per ADS or over 33.6%, to  
11 close at \$23.00 per ADS on December 17, 2019, from its December 16, 2019  
12 close at \$34.68, damaging investors.

13 75. Then, on January 8, 2020, NMC issued a press release entitled  
14 “KBBO pricing announcement” which acknowledged and downplayed Defendant  
15 K. Bin Butti and H.E. Bin Butti’s 31.2 million shares sell-off, which equates to  
16 roughly 15% of the Company, from January 7, 2020.

17 76. On this news, NMC ADSs fell \$6.48 per ADS, or over 28.4%, to  
18 close at \$16.36 per ADS on January 8, 2020 from its January 6, 2020 close at  
19 \$22.84, further damaging investors.

20 77. Then, on February 14, 2020, NMC issued a press release with  
21 preliminary share data, unverified, provided by Defendant K. Bin Butti, H.E. Bin  
22 Butti, and Defendant Shetty. The press release confirmed the need for greater  
23 clarity from its long-time principal shareholders, stating:

24  
25 The Company continues urgently to seek clarity from Dr. B.R.  
26 Shetty, Khalifa Bin Butti and H.E. Saeed Bin Butti in relation to the  
27 above arrangements and their respective shareholdings, and  
28 encourages Dr. B.R. Shetty, Khalifa Bin Butti and H.E. Saeed Bin

1 Butti, and their advisers, to agree the legal position in relation to the  
2 ownership of the Ordinary Shares in question without further delay.

3 78. That same day, NMC announced that Defendant K. Bin Butti had  
4 resigned as a Director effective immediately.

5 79. On this news, NMC ADSs fell \$0.54 per ADS, or almost 5%, to  
6 close at \$10.40 per ADS on February 14, 2020, further damaging investors.

7 80. Then on February 17, 2020, NMC announced that Abdulrahman  
8 Basaddiq and Hani Buttikhi had both resigned as Directors of the Company. Both  
9 were appointed to the Board of Directors by the principal shareholder group of  
10 Defendant K. Bin Butti, H.E. Bin Butti, and Defendant Shetty.

11 81. Also on February 17, 2020, NMC announced that Defendant Shetty  
12 had resigned as Joint-Non Executive Chairman and as a Director of the  
13 Company.

14 82. Then, on February 18, 2020, NMC announced an update to  
15 Defendant Shetty's shares of the Company. The update announced that a bank  
16 account for BRS International Holding Ltd ("BRS International"), of which  
17 Defendant Shetty is the sole shareholder, had sold over 10 million shares of NMC  
18 ordinary shares between February 3 and 6, 2020.

19 83. On this news, NMC ADSs fell \$0.74 per ADS, or over 6.5%, to  
20 close at \$10.48 per ADS on February 19, 2020, further damaging investors.

21 84. Then on February 24, 2020, BRS International, announced that  
22 Defendant Shetty "had pledged 7 million of the company's shares as security for  
23 debt" to Goldman Sachs. It was also announced that Defendant Shetty only  
24 "currently has a 9.81% interest" in NMC.

25 85. On this new NMC ADSs fell \$0.66 per ADS, or over 5.7%, to close  
26 at \$10.81 per ADS on February 24, 2020, further damaging investors.  
27  
28

1 86. Then, on March 10, 2020, the *Financial Times* published the article  
2 titled "NMC Health Discovers Almost \$3bn of Debt Hidden from Its  
3 Board" which continued to disclose NMC's lack of internal controls and under  
4 reporting of debt reporting.

5 87. Further on March 10, 2020, *Bloomberg* published the article titled  
6 "Abu Dhabi Insurer Steps In to Help NMC Health Pay Salaries" reporting that  
7 an insurer was assisting to pay NMC's expenses, stating the following in  
8 pertinent part:

9 An Abu Dhabi-owned insurer is helping NMC Health Plc pay  
10 overdue bills, according to people familiar with the matter, in what  
11 could be a sign the emirate is stepping in to help the embattled  
12 hospital operator.

13 The National Health Insurance Co., known as Daman, is speeding up  
14 payments to Abu Dhabi-based NMC so it can pay salaries and other  
15 invoices, the people said.

16 88. On this news, NMC ADSs fell \$3.28 per ADS, or almost 64%, to  
17 close at \$1.85 per ADS on March 10, 2020, further damaging investors.

18 89. As a result of Defendants' wrongful acts and omissions, and the  
19 precipitous decline in the market value of the Company's securities, Plaintiff and  
20 other Class members have suffered significant losses and damages.

21 **PLAINTIFF'S CLASS ACTION ALLEGATIONS**

22 90. Plaintiff brings this action as a class action pursuant to Federal Rule  
23 of Civil Procedure 23(a) and (b)(3) on behalf of a class consisting of all persons  
24 other than defendants who acquired NMC securities publicly traded on the OTC  
25 Pink during the Class Period, and who were damaged thereby (the "Class").  
26 Excluded from the Class are Defendants, the officers and directors of NMC,  
27 members of the Individual Defendants' immediate families and their legal  
28

1 representatives, heirs, successors or assigns and any entity in which Officer or  
2 Director Defendants have or had a controlling interest.

3 91. The members of the Class are so numerous that joinder of all  
4 members is impracticable. Throughout the Class Period, NMC securities were  
5 actively traded on the OTC Pink. While the exact number of Class members is  
6 unknown to Plaintiff at this time and can be ascertained only through appropriate  
7 discovery, Plaintiff believes that there are hundreds, if not thousands of members  
8 in the proposed Class.

9 92. Plaintiff's claims are typical of the claims of the members of the  
10 Class as all members of the Class are similarly affected by defendants' wrongful  
11 conduct in violation of federal law that is complained of herein.

12 93. Plaintiff will fairly and adequately protect the interests of the  
13 members of the Class and has retained counsel competent and experienced in  
14 class and securities litigation. Plaintiff has no interests antagonistic to or in  
15 conflict with those of the Class.

16 94. Common questions of law and fact exist as to all members of the  
17 Class and predominate over any questions solely affecting individual members of  
18 the Class. Among the questions of law and fact common to the Class are:

- 19
- 20 • whether the Exchange Act was violated by Defendants' acts as  
21 alleged herein;
  - 22 • whether statements made by Defendants to the investing public  
23 during the Class Period misrepresented material facts about the  
24 financial condition and business of NMC;
  - 25 • whether Defendants' public statements to the investing public during  
26 the Class Period omitted material facts necessary to make the
- 27
- 28

1 statements made, in light of the circumstances under which they  
2 were made, not misleading;

- 3 • whether the Defendants caused NMC to issue false and misleading  
4 filings during the Class Period;
- 5 • whether Defendants acted knowingly or recklessly in issuing false  
6 filings;
- 7 • whether the prices of NMC securities during the Class Period were  
8 artificially inflated because of the Defendants' conduct complained  
9 of herein; and
- 10 • whether the members of the Class have sustained damages and, if so,  
11 what is the proper measure of damages.

12 95. A class action is superior to all other available methods for the fair  
13 and efficient adjudication of this controversy since joinder of all members is  
14 impracticable. Furthermore, as the damages suffered by individual Class  
15 members may be relatively small, the expense and burden of individual litigation  
16 make it impossible for members of the Class to individually redress the wrongs  
17 done to them. There will be no difficulty in the management of this action as a  
18 class action.

19 96. Plaintiff will rely, in part, upon the presumption of reliance  
20 established by the fraud-on-the-market doctrine in that:

- 21 • NMC ADSs met the requirements for listing, and were listed and  
22 actively traded on the OTC Pink, an efficient market;
- 23 • NMC regularly communicated with public investors via established  
24 market communication mechanisms, including through the regular  
25 dissemination of press releases via major newswire services and  
26 through other wide-ranging public disclosures, such as  
27

28



1 above, which they knew or deliberately disregarded were misleading in that they  
2 contained misrepresentations and failed to disclose material facts necessary in  
3 order to make the statements made, in light of the circumstances under which  
4 they were made, not misleading.

5 102. Defendants violated §10(b) of the 1934 Act and Rule 10b-5 in that  
6 they:

- 7 • employed devices, schemes and artifices to defraud;
- 8 • made untrue statements of material facts or omitted to state  
9 material facts necessary in order to make the statements made,  
10 in light of the circumstances under which they were made, not  
11 misleading; or
- 12 • engaged in acts, practices and a course of business that  
13 operated as a fraud or deceit upon plaintiff and others similarly  
14 situated in connection with their purchases of NMC securities  
15 during the Class Period.

16 103. Defendants acted with scienter in that they knew that the public  
17 documents and statements issued or disseminated in the name of NMC were  
18 materially false and misleading; knew that such statements or documents would  
19 be issued or disseminated to the investing public; and knowingly and  
20 substantially participated, or acquiesced in the issuance or dissemination of such  
21 statements or documents as primary violations of the securities laws. These  
22 defendants by virtue of their receipt of information reflecting the true facts of  
23 NMC, their control over, and/or receipt and/or modification of NMC's allegedly  
24 materially misleading statements, and/or their associations with the Company  
25 which made them privy to confidential proprietary information concerning NMC,  
26 participated in the fraudulent scheme alleged herein.

27  
28

1           104. Individual Defendants, who are the senior officers and/or directors  
2 of the Company, had actual knowledge of the material omissions and/or the  
3 falsity of the material statements set forth above, and intended to deceive Plaintiff  
4 and the other members of the Class, or, in the alternative, acted with reckless  
5 disregard for the truth when they failed to ascertain and disclose the true facts in  
6 the statements made by them or other NMC personnel to members of the  
7 investing public, including Plaintiff and the Class.

8           105. As a result of the foregoing, the market price of NMC securities was  
9 artificially inflated during the Class Period. In ignorance of the falsity of  
10 Defendants' statements, Plaintiff and the other members of the Class relied on the  
11 statements described above and/or the integrity of the market price of NMC  
12 securities during the Class Period in purchasing NMC securities at prices that  
13 were artificially inflated as a result of Defendants' false and misleading  
14 statements.

15           106. Had Plaintiff and the other members of the Class been aware that the  
16 market price of NMC securities had been artificially and falsely inflated by  
17 Defendants' misleading statements and by the material adverse information  
18 which Defendants did not disclose, they would not have purchased NMC  
19 securities at the artificially inflated prices that they did, or at all.

20           107. As a result of the wrongful conduct alleged herein, Plaintiff and  
21 other members of the Class have suffered damages in an amount to be established  
22 at trial.

23           108. By reason of the foregoing, Defendants have violated Section 10(b)  
24 of the 1934 Act and Rule 10b-5 promulgated thereunder and are liable to the  
25 plaintiff and the other members of the Class for substantial damages which they  
26 suffered in connection with their purchase of NMC securities during the Class  
27 Period.  
28

**COUNT II**

**Violations of Section 20(a) of the Exchange Act**

**Against the Individual Defendants**

1  
2  
3  
4 109. Plaintiff repeats and realleges each and every allegation contained in  
5 the foregoing paragraphs as if fully set forth herein.

6 110. During the Class Period, the Individual Defendants participated in  
7 the operation and management of NMC, and conducted and participated, directly  
8 and indirectly, in the conduct of NMC's business affairs. Because of their senior  
9 positions, they knew the adverse non-public information about NMC's  
10 misstatement of revenue and profit and false financial statements.

11 111. As officers and/or directors of a publicly owned company, the  
12 Individual Defendants had a duty to disseminate accurate and truthful information  
13 with respect to NMC's financial condition and results of operations, and to  
14 correct promptly any public statements issued by NMC which had become  
15 materially false or misleading.

16 112. Because of their positions of control and authority as senior officers,  
17 the Individual Defendants were able to, and did, control the contents of the  
18 various reports, press releases and public filings which NMC disseminated in the  
19 marketplace during the Class Period concerning NMC's results of operations.  
20 Throughout the Class Period, the Individual Defendants exercised their power  
21 and authority to cause NMC to engage in the wrongful acts complained of herein.  
22 The Individual Defendants therefore, were "controlling persons" of NMC within  
23 the meaning of Section 20(a) of the Exchange Act. In this capacity, they  
24 participated in the unlawful conduct alleged which artificially inflated the market  
25 price of NMC securities.  
26  
27  
28

1 113. By reason of the above conduct, the Individual Defendants are liable  
2 pursuant to Section 20(a) of the Exchange Act for the violations committed by  
3 NMC.

4 **PRAYER FOR RELIEF**

5 **WHEREFORE**, plaintiff, on behalf of himself and the Class, prays for  
6 judgment and relief as follows:

7 (a) declaring this action to be a proper class action, designating plaintiff  
8 as Lead Plaintiff and certifying plaintiff as a class representative under Rule 23 of  
9 the Federal Rules of Civil Procedure and designating plaintiff’s counsel as Lead  
10 Counsel;

11 (b) awarding damages in favor of plaintiff and the other Class members  
12 against all defendants, jointly and severally, together with interest thereon;

13 awarding plaintiff and the Class reasonable costs and expenses incurred in  
14 this action, including counsel fees and expert fees; and

15 (d) awarding plaintiff and other members of the Class such other and  
16 further relief as the Court may deem just and proper.

17 **JURY TRIAL DEMANDED**

18 Plaintiff hereby demands a trial by jury.

19  
20  
21 Dated: March 10, 2020

**THE ROSEN LAW FIRM, P.A.**

22 */s/Laurence M. Rosen*  
23 Laurence M. Rosen (SBN 219683)  
24 355 South Grand Avenue, Suite 2450  
25 Los Angeles, CA 90071  
26 Telephone: (213) 785-2610  
27 Facsimile: (213) 226-4684  
28 Email: lrosen@rosenlegal.com